Aether's margin rebounds, but remains below its Q3FY26 peak
Standalone operating margin widened 5.06 percentage points QoQ as costs stayed largely flat, though other income remained material to pre-tax profit.
Filed 31 Jul 2026, 14:11 IST · Aether Industries Ltd (AETHER)
Key takeaways
- Standalone revenue grew 19.68% YoY, but expenses rose faster at 21.36%, limiting operating profit growth to 16.12%.
- Operating margin recovered 5.06 percentage points QoQ to 31.09% as revenue grew 8.09% while expenses rose only 0.71%.
- Other income contributed 14.96% of pre-tax profit, while the tax rate increased 2.21 percentage points YoY to temper reported profit growth.
Price around the results
Revenue growth lifted profit, but cost growth remained higher YoY
Aether Industries reported standalone revenue growth of 19.68% YoY in Q1FY27, while net profit increased 20.35% to Rs 48.31 cr. Sequentially, revenue rose 8.09% and operating profit increased 29.07%, showing a sharper recovery from the weak Q4FY26 operating base. The YoY gap between revenue and expenses meant operating profit grew more slowly than sales.
QoQ margin recovery came from cost containment
Operating margin widened 5.06 percentage points QoQ because expenses grew only 0.71% against 8.09% revenue growth. YoY, expenses grew 21.36% versus 19.68% for revenue, narrowing margin by 0.95 percentage points. Interest expense fell 23.21% QoQ, but depreciation rose 18.86% and the tax rate increased 4.82 percentage points QoQ. Other income accounted for 14.96% of pre-tax profit, so reported earnings included a material non-operating contribution.
Margin recovered from Q4FY26 but stayed below Q3FY26
The operating margin moved from 35.67% in Q3FY26 to 26.03% in Q4FY26 and 31.09% in Q1FY27, marking a recovery rather than a return to the recent peak. Against 37 reported Commodities-sector peers, Aether's margin was 12.93 percentage points above the 18.16% median. Management said LSM volume fell 22% YoY because production lines were deliberately reallocated to CEM.
Management points to CRAMS, CEM and Magnum for the next phase
Management said CRAMS had more than 65 live projects in Q1, with 70% outside pharmaceuticals and agrochemicals, while Ascend began booking revenue and was operating in line with expectations. The company said products launched from Magnum are expected to start contributing revenue from Q2FY27, and that CRAMS and CEM are expected to reach 70% of revenue over the next couple of years. Management also maintained guidance of approximately 30% EBITDA margin for FY27 and said it is working to commercialise semiconductor and European-major CEM production blocks at Magnum by Q3FY27.
No post-result move yet; history is evenly split
The results were filed during market hours, so there is no post-result stock move to assess yet. Across the eight prior result reactions, the stock rose four times and fell four times, with a median absolute move of 3.29%.
Q1FY27 at a glance
Standalone figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 | Q4FY26 | QoQ | YoY |
|---|---|---|---|---|
| Revenue | ₹257 cr | ₹237 cr | +8.09% | +19.68% |
| Other income | ₹10 cr | ₹8 cr | +18.23% | +1692.73% |
| Expenses | ₹177 cr | ₹176 cr | +0.71% | +21.36% |
| Operating profit | ₹80 cr | ₹62 cr | +29.07% | +16.12% |
| Operating margin (%) | 31.09% | 26.03% | — | — |
| Interest | ₹4 cr | ₹5 cr | -23.21% | +8.92% |
| Depreciation | ₹20 cr | ₹17 cr | +18.86% | +57.33% |
| Profit before tax | ₹66 cr | ₹49 cr | +35.72% | +23.97% |
| Tax | ₹18 cr | ₹11 cr | +65.69% | +35.13% |
| Net profit | ₹48 cr | ₹38 cr | +27.33% | +20.35% |
| EPS (₹) | ₹3.64 | ₹2.86 | +27.27% | +20.13% |
Operating margin of 31.09% compares with a Commodities sector median of 18.16% across 37 peers that have reported Q1FY27.
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- CRAMS had over 65 live projects during Q1, with 70% in non-pharmaceutical and non-agrochemical sectors.
- Ascend began booking revenue during the quarter and its plant was running in line with expectations.
Guidance & outlook
- CRAMS and CEM are expected to reach 70% of revenue over the next couple of years.
- LSM products launched from Magnum are expected to begin contributing revenue from Q2 FY2027.
- The company maintains guidance of approximately 30% EBITDA margin for FY2027.
Expansion
- The new R&D centre is expected to be ready by Q2 FY2028, with ₹1,000 million of capex, 120 fume hoods and eight technical labs.
- Magnum’s total capital expenditure was approximately ₹833 million in Q1 FY2027.
- The company is working to commercialise semiconductor and European-major CEM production blocks at Magnum by Q3 FY2027.
New products
- LSM products from Magnum were launched during the quarter and are expected to contribute revenue from Q2 FY2027.
New initiatives
- The company completed installation of 18 additional fume hoods and an NMR machine at its R&D centre during Q1.
- The new NMR capability supports bids and opportunities in oil and gas, material science, application testing and product development.
- The company launched LSM products from Magnum during the quarter.
Problems & risks
- LSM volume fell 22% year on year because certain production lines were reallocated to CEM.
What to watch
- Whether operating margin holds above 31.09% after the Q1FY27 recovery.
- Whether LSM volume recovers from the 22% YoY decline as Magnum products begin contributing from Q2FY27, as management said.
- Whether CRAMS and CEM progress toward management's stated 70% revenue mix over the next couple of years.